Compare BRID & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRID | MNOV |
|---|---|---|
| Founded | 1932 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.0M | 66.9M |
| IPO Year | 1995 | 2004 |
| Metric | BRID | MNOV |
|---|---|---|
| Price | $7.44 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 3.0K | ★ 55.9K |
| Earning Date | 03-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $174,257,000.00 | $2,360,807.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 4.21 | ★ 194.15 |
| 52 Week Low | $7.00 | $1.13 |
| 52 Week High | $8.73 | $1.96 |
| Indicator | BRID | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 49.46 | 50.24 |
| Support Level | $7.39 | $1.40 |
| Resistance Level | $8.06 | $1.60 |
| Average True Range (ATR) | 0.33 | 0.06 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 23.80 | 38.68 |
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The two business segments are: the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches, among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, mass merchandise, and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.